



Enhancer redundancy in development and disease

Evgeny Z. Kvon^{1,2,3}✉, Rachel Waymack¹, Mario G. Elabd¹ and Zeba Wunderlich^{1,3}✉

Abstract | Shadow enhancers are seemingly redundant transcriptional cis-regulatory elements that regulate the same gene and drive overlapping expression patterns. Recent studies have shown that shadow enhancers are remarkably abundant and control most developmental gene expression in both invertebrates and vertebrates, including mammals. Shadow enhancers might provide an important mechanism for buffering gene expression against mutations in non-coding regulatory regions of genes implicated in human disease. Technological advances in genome editing and live imaging have shed light on how shadow enhancers establish precise gene expression patterns and confer phenotypic robustness. Shadow enhancers can interact in complex ways and may also help to drive the formation of transcriptional hubs within the nucleus. Despite their apparent redundancy, the prevalence and evolutionary conservation of shadow enhancers underscore their key role in emerging metazoan gene regulatory networks.

Expression domains

The specific tissues or cell types where an enhancer drives expression of its target gene.

Phenotypic robustness

The ability of a system to reliably produce a wild-type phenotype in the presence of environmental (for example, temperature) or genetic (for example, decreased expression levels of an upstream transcription factor) stress.

Transcriptional enhancers are non-coding DNA elements that are typically 200–2,000 bp in length and drive gene expression patterns in space and time. Enhancers contain numerous binding sites for sequence-specific transcription factors (TFs), which upon binding to the enhancer recruit cofactors to activate transcription from a target core promoter. A typical metazoan gene contains multiple cell type-specific enhancers spread across large genomic distances, which collectively produce a complex gene expression pattern (for general reviews on enhancers, see REFS^{1–7}). The classic textbook view is that, within a gene locus, different enhancers drive distinct spatiotemporal aspects of gene expression^{1,7}. However, this model is an oversimplification because enhancers regulating the same gene often display overlapping or partially overlapping spatiotemporal activity^{8–12}. Examples of such redundant enhancers were often overlooked, until 2008, when Mike Levine and colleagues introduced the term ‘shadow enhancer’¹³. In that study, redundant enhancers were designated either as ‘primary’ (the enhancers closest to the core promoter) or as ‘shadow’ (the enhancers located at a greater distance from the core promoter)¹³. This distinction was later revised owing to a lack of functional differences between primary and shadow enhancers^{14,15}. In this Review, we define ‘shadow enhancers’ as sets of enhancers that regulate a common target gene and drive expression patterns that partially or completely overlap in space and time. This definition has become increasingly accepted in the gene regulation community^{14–24}. The degree of overlap required for enhancers to qualify as shadow enhancers depends on what is functionally meaningful in a given

biological context. In the early *Drosophila melanogaster* embryo, characterized shadow enhancers typically overlap in more than 50% of their expression domains at a given time point (TABLE 1). However, in other contexts, such as the nematode nervous system, even an overlap in a single neuron cell can be biologically significant²⁵.

The existence of shadow enhancers has raised fundamental questions about the purpose and evolutionary origins of this apparent redundancy. In development, multiple mechanisms of regulatory redundancy ensure accurate patterning. Examples include redundant genetic interactions and multiple binding sites for the same TF within an enhancer. Shadow enhancers are increasingly appreciated as another mechanism of redundancy that provides a safeguard against genetic and environmental perturbations. Seminal studies in *D. melanogaster* demonstrated that shadow enhancers improve the precision of gene expression and phenotypic robustness during animal development, especially under conditions of physiological or genetic stress^{26–28}. Later work in mammals confirmed that shadow enhancers similarly confer robustness to mammalian development^{18,29,30}. Together, these studies suggest that shadow enhancers may be a common mechanism of developmental robustness in animals. Understanding the mechanism of shadow enhancer function will therefore illuminate how multi-enhancer architecture can determine the robustness or fragility of a developmental process to perturbation.

Recent advances in enhancer mapping and novel genetic and imaging tools for enhancer analysis have deepened our understanding of shadow enhancer

¹Department of Developmental and Cell Biology, University of California, Irvine, Irvine, CA, USA.

²Department of Ecology and Evolutionary Biology, University of California, Irvine, Irvine, CA, USA.

³These authors contributed equally: Evgeny Z. Kvon, Zeba Wunderlich.

✉e-mail: ekvon@uci.edu; zeba@uci.edu

<https://doi.org/10.1038/s41576-020-00311-x>

Table 1 | Examples of shadow enhancers in different organisms

Tissue or cell type	Genes with reported shadow enhancers	Gene class	Maximum distance between shadow enhancers (kb)	Refs
Plant				
Anthers, pollen	<i>LAT</i>	Signalling	~3	50
Leaf cells	<i>rbcS-8B</i>	Signalling	~1	51
Worm				
Nervous system	<i>cog-1, ric-4, ric-19, snb-1, unc-10, unc-11, unc-31, unc-64, unc-108</i>	TF, pan-neuronal genes	~10	25,147
Fruit fly				
Neurogenic ectoderm	<i>vnd, brk, sog, dan, SoxN</i>	TF, signalling	~40	10,13,43
Dorsal ectoderm	<i>tup</i>	TF	~20	43
A–P blastoderm	<i>slp1, wg, hb, Kr, kni, gt, oc</i> (also known as <i>otd</i>), <i>ems, hkb, fkh, Abd-B, prd</i>	TF, signalling	~30	28,148,149
Mesoderm	<i>sna, miR-1, ade5, Traf1, rols, CG42788, CadN</i>	Various	~10	10,16,27
Salivary glands	<i>sens</i>	TF	~2	43
Epidermis	<i>Ser, svb, y</i>	Various	~40	26,53,150
Wing imaginal disc	<i>brk</i>	Signalling	~10	56
Nervous system	<i>Ddc</i>	Signalling	~1	151
Eye	<i>Dve, dac</i>	TF, signalling	~15	55,87
Zebrafish				
Brain	<i>krox20</i>	TF	~100	152
Fin	<i>shh</i>	Signalling	~2	19
Neural tube	<i>shh</i>	Signalling	~2	57
Mouse				
Brain, neural tube	<i>Otx2, Pomc, Shh, Arx, Ngn1</i>	TF, signalling	~800	11,12,58, 78,153,154
Neural crest	<i>Pax3</i>	TF	~30	155
Eye	<i>Pax6, Cryaa</i>	TF, structural	~150	18,156
Blood	α -Globin and β -globin genes, <i>Igk, Igh</i>	Haemoglobin subunits, immune response	~25	68,91,114,130
Limb	<i>Gli3, Sox9, Shox2, Ihh, Hoxd, Hoxa, Tbx4</i>	TF, signalling	~1,200	29,59,104,157,158
Tooth	<i>Shh</i>	Signalling	~100	30
Gut	<i>Cdx2</i>	TF	~7	23
Human				
Liver	<i>APOE</i>	Metabolism	~10	63
Blood	β -Globin genes	Haemoglobin subunits	~15	60,61
Eye	<i>ATOH7</i>	TF	~20	22,159
Kidney	<i>REN</i>	Signalling	~6	62

Only non-adjacent enhancers are included. A–P, anterior–posterior; TF, transcription factor.

function and their crucial role in development and human disease. Chromatin profiling and 3D genome profiling by large consortia such as ENCODE, FANTOM, the Roadmap Epigenomics Consortium and the 4D Nucleome Project have produced genome-wide maps of putative enhancers across many cell types, tissues and time points, both in mice and in humans^{31–36}. Large-scale transgenic reporter assays have enabled

characterization of *in vivo* activity for thousands of bona fide enhancers^{37–42}, revealing an ever-growing number of putative shadow enhancers^{25,43}. Efficient genome and epigenome editing of enhancers within their native genomic context has enabled analysis of enhancer requirements for organismal function^{44–47}. Finally, quantitative live imaging methods have allowed the assessment of shadow enhancer functions in whole

Evolutionary constraint

Factors that serve to limit the divergence of a particular phenotype; conserved DNA sequences are interpreted as evidence of evolutionary constraint.

Super-enhancers or stretch enhancers

Clusters of enhancers that are strongly occupied by transcription factors, co-activators or modified histones (as measured by chromatin immunoprecipitation followed by sequencing) and that control key cell identity genes.

Enhancer-derived RNAs

(eRNAs). Short, non-coding RNAs that are transcribed from the DNA of enhancer sequences and whose transcription correlates with enhancer activity.

embryos^{48,49}. These advances have enabled scientists to address key questions in shadow enhancer biology: how common are shadow enhancers in the genomes of different animals? Is there a function of shadow enhancers beyond conferring robustness? How do shadow enhancers work together in the context of the 3D genome? What is the role of shadow enhancers in human disease?

In this Review, we discuss key points that have emerged from these technological advances. We review how these studies have provided insights into the prevalence of shadow enhancers in bilaterian genomes and their crucial role in ensuring normal development under conditions of stress. We illustrate how the action of multiple shadow enhancers on a single promoter can fine-tune gene expression. We also discuss a potential role of shadow enhancers in organizing ‘hubs’ of transcriptional activity in the nucleus. We review the evidence that shadow enhancers frequently regulate genes implicated in human disease and buffer gene expression against mutations in non-coding regulatory DNA. Lastly, we discuss theories for the origin of shadow enhancers and their unexpectedly high evolutionary constraint. We synthesize mechanistic studies of shadow enhancers in *D. melanogaster* with emerging genetic manipulations of enhancers in mice to provide a cohesive picture of the role of regulatory redundancy in animal systems.

Genomic prevalence of shadow enhancers

Enhancers with redundant activity have been described for more than 30 years, with examples from plants^{50,51}, flies^{8–10,52–56}, zebrafish⁵⁷, mice^{11,12,58,59} and humans^{60–63} (TABLE 1). These individual gene locus studies showed that shadow enhancers are found in a broad set of multicellular organisms, but within a single genome the prevalence of shadow enhancers was unknown. Since these studies were often focused on enhancers that control important developmental regulators, it was also not clear whether shadow enhancers are associated with other classes of genes. Substantial increases in the throughput of enhancer identification and characterization (reviewed in REFS^{1,7,64}) have allowed researchers to determine the prevalence of shadow enhancers genome-wide.

Genome-wide enhancer predictions based on chromatin features, such as chromatin accessibility, histone modifications and TF binding, have suggested that shadow enhancers might be common in animal genomes. Using a combination of mesodermal TF chromatin immunoprecipitation data and computational models, Cannavo et al. generated an exhaustive catalogue of muscle development enhancers in *D. melanogaster*¹⁶. They found that nearly two thirds of examined muscle developmental genes were controlled by shadow enhancers and that most of these genes had three or more predicted shadow enhancers¹⁶. A genome-wide analysis combining ENCODE transcriptomic and epigenomic data from multiple mouse tissues showed ample enhancer redundancy among developmentally regulated genes^{29,35}. Whereas housekeeping genes are typically controlled by one enhancer, developmentally regulated genes can have ten or more shadow enhancers (TABLE 2).

In human cells, chromatin immunoprecipitation-based profiling of TFs, cofactors, chromatin regulators

and enhancer-associated histone modifications revealed that hundreds of key cell identity genes are regulated by large clusters of putative transcriptional enhancers (super-enhancers or stretch enhancers), which could be clusters of shadow enhancers^{65–70}. Many mammalian enhancers, including human enhancers, are actively transcribed, and the presence of enhancer-derived RNAs (eRNAs) was suggested to be predictive of enhancer activity^{31,71,72}. Profiling of eRNAs using cap analysis of gene expression (CAGE) across hundreds of human cell lines and tissues revealed that ~80% of 2,206 examined genes were associated with two or more co-transcribed enhancers³¹, suggesting that enhancer redundancy is common in the human genome. Computational approaches based on epigenomic data have also found widespread evidence for shadow enhancers in the human genome, particularly in association with developmental and disease-causing genes⁷³.

Most chromatin and TF profiling methods are based on indirect measures of enhancer activity, which is why they have to be followed by functional testing. Large-scale transgenic enhancer-reporter screens have verified that bona fide redundant enhancers are common in the *D. melanogaster* and *Caenorhabditis elegans* genomes. An analysis of nearly 8,000 enhancer fragments during *D. melanogaster* embryogenesis revealed that many developmentally regulated genes are controlled by two or more enhancers with overlapping activities⁴³ (TABLE 1). Single-neuron imaging data from hundreds of enhancer-reporter constructs in *C. elegans* demonstrated that shadow enhancers control nearly all 23 pan-neuronal genes studied²⁵. Even within a single cell type, massively parallel reporter assays have shown that hundreds of genes in *D. melanogaster* cell lines are potentially controlled by two or more redundant enhancers⁷⁴. Taken together, these studies indicate that enhancers driving overlapping expression patterns are common in organisms from worms to insects to mammals and are preferentially, albeit not exclusively, associated with the control of developmental genes.

Shadow enhancers confer robustness

Several early studies in *D. melanogaster* demonstrated that shadow enhancers are required to drive normal development under conditions of stress, but they may be dispensable in ‘ideal’ conditions. For example, the TF Snail is required for normal gastrulation, and its expression in mesoderm is controlled by two shadow enhancers. Deletion of either of *snail*’s shadow enhancers, in the context of a bacterial artificial chromosome transgene, caused no apparent gastrulation defect²⁷. However, individual shadow enhancer deletion led to abnormal gastrulation under elevated temperatures or in a sensitized genetic background where the dosage of an upstream regulator, Dorsal, was reduced²⁷. Similarly, a deletion of three of six epidermal shadow enhancers of *shavenbaby* (also known as *ovo*) had no phenotype under normal conditions but caused a decrease of trichome numbers under temperature or genetic stress conditions³⁶.

Advances in genome editing have enabled the efficient introduction of multiple mutations in mice^{75–77}, enabling experiments to test whether shadow enhancers

Haplosufficiency

A property of an allele whereby a single copy of that allele in a diploid organism is sufficient to drive a wild-type phenotype.

Expression noise

Variability in gene expression across either time or space, owing to the stochastic nature of the molecular interactions underlying gene expression.

similarly provide developmental robustness in vertebrates. Whereas single shadow enhancer deletions in mice typically show either mild or no observable phenotypes, double enhancer deletions show severe phenotypes, often comparable to complete gene loss of function in relevant tissues^{18,29,30,68,78}. Together, these observations indicate that both enhancers regulate the gene and at least one shadow enhancer is required for normal development in ideal conditions (FIG. 1). Despite driving similar expression patterns, the individual shadow enhancers are not strictly redundant. In a sensitized genetic background with a reduced dosage of the target gene, single enhancer deletions show abnormal phenotypes, indicating that shadow enhancers can confer robustness to genetic perturbations (FIG. 1). This pattern has been demonstrated for *Pax6*, a gene required for early eye lens morphogenesis¹⁸, *Shh* in developing teeth³⁰ and several limb development loci²⁹.

Taken together, both fruit fly and mouse studies emphasize that, while ostensibly redundant in the expression patterns they drive, the necessity of shadow enhancers is revealed when enhancer-deficient organisms are placed in stressful conditions. How shadow enhancers provide this robustness remains an area of open investigation, and more than one mechanism may be at play. One potential scenario is that each enhancer alone can drive sufficient levels of gene expression for normal development, similar to the haplosufficiency of many developmental genes. By having multiple enhancers, the probability that at least one is active increases, increasing the chance for normal development^{14,24}. A second potential mechanism was suggested by the observation that a pair of *D. melanogaster* shadow enhancers controlling the gene *Kruppel* are regulated by different combinations of TFs¹⁷. By responding to different sets of TFs, but converging on a single output, shadow enhancers could provide a mechanism to buffer gene expression against not only mutations in their sequences

but, more importantly, perturbations in one of their upstream TFs (FIG. 2). Experimental measurements show that *Kruppel*'s independently controlled shadow enhancers drive lower expression noise than single or duplicated enhancer configurations, suggesting that simple enhancer duplications may not be sufficient to provide phenotypic robustness⁷⁹. Independent regulation of shadow enhancers may be a widespread mechanism to confer robustness, as many mesodermal shadow enhancers are bound by different combinations of upstream TFs¹⁶.

Modes of shadow enhancer interactions

The interactions between shadow enhancers can fine-tune the expression pattern of their target gene. Within an individual cell, shadow enhancers can interact in one of four ways: additively, superadditively (driving more expression than the sum of the individual enhancer activities), subadditively (driving less expression than the sum of the individual enhancer activities) or repressively (FIG. 3). The classic view of enhancers is implicitly additive, as each enhancer functions independently to build up a gene's total expression pattern⁸⁰. Several studies in the fruit fly embryo used live mRNA tracking of reporter constructs to measure shadow enhancer interaction. Shadow enhancers can act additively, with a pair of shadow enhancers driving expression roughly equal to the sum of the individual enhancers' expression output. For example, such additive behaviour is seen for the shadow enhancers controlling the genes *knirps* and *hunchback*⁸¹. However, this behaviour can change depending on the cell type or time point because of the varying levels and identities of TFs bound to each enhancer. For example, the *knirps* shadow enhancers act additively at some time points and superadditively at others, indicating the presence of synergistic interactions between shadow enhancers⁸¹. The shadow enhancers controlling the mouse *Pomc* gene also show superadditivity at some

Table 2 | Examples where genes are controlled by more than two shadow enhancers

Tissue or cell type	Enhancer identification method	Method of assigning enhancers to genes	Genes	Number of shadow enhancers per gene	Ref.
Fruit fly					
S2 cells (macrophage-like)	MPRA	Genomic proximity	Various (203 genes)	≥5	74
Embryonic mesoderm	Mesoderm TF ChIP	Genomic proximity and correlation with gene expression	Various (150 genes)	≥3	16
Mouse					
Embryonic limb	H3K27 acetylation ChIP	Genomic proximity within a TAD and correlation with gene expression	Limb TF genes (41 genes)	Median of 8	29
Embryonic heart	H3K27 acetylation ChIP	Genomic proximity within a TAD and correlation with gene expression	Heart TF genes (27 genes)	Median of 10	29
Embryonic forebrain	H3K27 acetylation ChIP	Genomic proximity within a TAD and correlation with gene expression	Forebrain TF genes (21 genes)	Median of 4	29

ChIP, chromatin immunoprecipitation; H3K27, histone H3 Lys27; MPRA, massively parallel reporter assay; TAD, topologically associating domain; TF, transcription factor.




Fig. 1 | **Shadow enhancers confer phenotypic robustness in mammals.** In mice, many individual shadow enhancer deletions yield no observable phenotypes. However, either the deletion of individual shadow enhancers in a sensitized background or the deletion of pairs of shadow enhancers leads to observable phenotypes. Schematics of perturbations (left) and resulting phenotypes in mice (right) are shown for two gene loci: *Gli3* (REF.²⁹) and *Pax6* (REFS^{18,160}). *GLI3* is critical for proper limb development, and knockout of the encoding gene causes the formation of extra digits (among other phenotypes)¹⁶¹. Skeletal phenotypes in the absence of individual *Gli3* shadow enhancers, pairs of shadow enhancers or an individual shadow enhancer in a sensitized background are shown (centre). Red asterisks indicate the presence of extra digits. *Pax6*-deficient mice have arrested eye development and no lens formation^{162,163}. A schematic diagram of an eye section showing a developing lens in the absence of individual *Pax6* shadow enhancers, pairs of shadow enhancers or an individual shadow enhancer in a sensitized background is shown (centre right). A schematic of gene dosage in the mutants is shown on the right. EnhA, enhancer A; EnhB, enhancer B. Adapted from REF.²⁹, Springer Nature Limited.

time points and additivity at others⁸². In the case of the *D. melanogaster hunchback* gene, the behaviour depends on the concentration of its primary activating TF, Bicoid (Bcd). In cells where Bcd concentration is low, the two enhancers combine additively, but in cells where Bcd concentration is high, the enhancers combine subadditively⁸¹. Such subadditive behaviour could

indicate the presence of competition between shadow enhancers for promoter occupancy. Subadditivity has also been observed in the case of strong enhancers in the *Kruppel* locus⁸³.

In addition to the interactions described above, one shadow enhancer can partially or completely repress the other, decreasing or shutting off expression entirely.

Quenching

A form of repression whereby the binding of repressive transcription factors within an enhancer sequence blocks the binding of activating transcription factors.

In *D. melanogaster* embryonic cells at the boundary of the *knirps* and *Kruppel* expression domains, shadow enhancers can repress each other's activity, yielding sharper expression patterns than either enhancer alone⁸⁴. Examples from the *short gastrulation*, *snail* and *defective proventriculus* loci show some shadow enhancer deletions can lead to higher expression levels, suggesting that one shadow enhancer represses the other^{81,85–87}. The mechanisms that explain this repression are still unclear and could include quenching, interference of enhancer–promoter looping, or the spread of repressive chromatin marks.

On the tissue or organismal level, shadow enhancers can interact in nuanced ways to fine-tune both the levels and the patterns of gene expression. The way that multiple shadow enhancers interact can vary from cell to cell, depending on the *trans*-regulatory environment. Multiple potential mechanisms may explain the variety of behaviours observed. For example, subadditive behaviours between two strong shadow enhancers might occur because their target promoter has reached its maximum expression rate or because the enhancers are competing with each other for promoter access^{3,81,83}. Superadditive behaviours might arise if there is synergy between the TFs bound at each shadow enhancer^{3,88}. Additional experiments that manipulate the number of shadow enhancers in a locus or their TF-binding content, combined with experiments that probe the molecular details of shadow enhancer function (described later), may further illuminate the mechanisms at play.

Shadow enhancers and nuclear organization

The experiments described in the previous section measured the gene expression driven by shadow enhancers across the entire organism. How do shadow enhancers operate on a molecular level? Enhancers can regulate their target core promoters over long distances, sometimes up to several megabases, a process mediated by TFs, co-activators and RNA polymerase II. Many studies observe the establishment of enhancer–promoter interactions coordinately with gene transcription. Various mechanisms and models of enhancer–promoter communication have been proposed, including tracking, linking, looping and combinations thereof (for general reviews on enhancer–promoter interactions, see REFS^{2,4,89,90}). The prevalence of shadow enhancers raises an intriguing question about how multiple enhancers interact with a single core promoter. Do shadow enhancers loop to the target promoter in a coordinated fashion, or is it a dynamic process with multiple enhancers competing for the same promoter (FIG. 4a)? Distinguishing between these possibilities may help to illuminate how multiple shadow enhancers combine their activities to specify patterns and levels of gene expression.

Experiments based on chromosome conformation capture provide indirect support for simultaneous promoter activation, as individual shadow enhancers often form contacts between each other and the target gene in the same cell^{68,91–94}. These capture experiments were performed in populations of fixed cells and do not reflect the dynamics of enhancer–promoter interactions




Fig. 2 | Independent TF inputs to shadow enhancers lead to more robust transcriptional output. Shared and separated transcription factor (TF) inputs to the individual shadow enhancers can have different effects on gene expression noise. In the case of separated inputs, shadow enhancers regulating the same target gene do not share any of the same TF regulators (top left), while in the case of shared inputs, shadow enhancers are regulated by the same set of TFs (top right). Below these two different models, we show the corresponding target gene expression dynamics in single cells as a function of time. Lower expression noise is seen with shadow enhancers with separated TF inputs than with shadow enhancers using shared TF inputs. See REF.⁷⁹ for more details.




Fig. 3 | **Shadow enhancers can combine in complex and varied ways.** In an individual cell (red circles), enhancers can interact additively, subadditively, superadditively, partially repressively or fully repressively, as shown in the bar graphs. Cartoon embryos depicting individual (yellow and green) and combined (brown) enhancer activities, measured in transgenic *Drosophila melanogaster*, are shown. Notably, the mechanism of interaction can vary from cell to cell, highlighting the importance of performing experiments in whole embryos. For example, two shadow enhancers can show each of these behaviours in different parts of their expression stripe, allowing them to combine to produce a sharper and stronger stripe than that produced by either individual enhancer.

and transcription from the target promoter. Live imaging of transcription in *D. melanogaster* embryos suggests that a single enhancer can simultaneously activate two different promoters, even those located on different chromosomes, leading to synchronized transcription bursts^{95,96}. Together, these studies suggest that enhancer–promoter loops can include more than two DNA elements. Therefore, it seems plausible that several shadow enhancers could simultaneously coordinate the expression of a single target promoter (FIG. 4a). A direct demonstration of such coordinated expression is challenging as it requires simultaneous labelling of several shadow enhancers and transcription from a target promoter. With the development of new live imaging tools, it may soon be possible to visualize how shadow enhancers activate target promoters in live nuclei^{97–100}.

The concept of dynamic ‘transcriptional hubs’ (or the related concepts of ‘nuclear microenvironments’ or less dynamic ‘transcriptional condensates’) challenges the simple enhancer–promoter looping model and provides a plausible model for promoter regulation by multiple shadow enhancers^{90,101–106}. These large hubs

(more than 300 nm) are formed by TFs, components of the core transcriptional machinery^{102,103} and RNA polymerase II (REFS^{105,107}) and may explain why some enhancers activate promoters even in the absence of close enhancer–promoter proximity^{108,109}. The hub model suggests that shadow enhancers and their target promoter can simultaneously participate in the same microenvironment, forming a multi-enhancer hub. The observation of transcriptional co-activator condensates on super-enhancer-associated genes provides support for this model^{65,102,103}. Recent work on the *D. melanogaster shavenbaby* locus showed that deleting one of the shadow enhancers results in decreased local density of the key activating TFs, suggesting that shadow enhancers are critical for maintaining high concentrations of TFs within the transcriptional hub¹¹⁰ (FIG. 4b). Through the formation of multi-enhancer transcriptional hubs with high concentrations of TFs, transcriptional co-activators and RNA polymerase II, shadow enhancers may increase phenotypic resilience to stress by buffering gene expression against environmental and genetic perturbations.

Transcription bursts
Periods of rapid transcription interspersed with periods of transcriptional silence.

Transcriptional hubs
Three-dimensional nuclear compartments (more than 300 nm) formed around actively transcribed genes with a high local concentration of transcription factors, co-activators, RNA polymerase II and other components of the core transcriptional machinery.




Fig. 4 | Interactions of shadow enhancers with target promoters. a | There are two possible models of enhancer–promoter looping. In the simultaneous looping model, enhancer A and enhancer B coordinately loop to the target core promoter to initiate transcription. In the alternating looping model, enhancer A competes with enhancer B, so, at a given time point, only one of the enhancers contacts the promoter. **b** | Multiple shadow enhancers may aid in the formation of transcriptional hubs by recruiting a high local amount of a master regulator transcription factor (TF; pink). Such transcriptional hubs can buffer gene expression against environmental stress and genetic perturbations¹⁰. WT, wild type.

Shadow enhancers and human disease

Many human genetic disorders are caused by mutations in developmental genes. A strong association of shadow enhancers with developmental genes suggests

that enhancer redundancy provides an important safeguard against deactivating non-coding mutations in *cis*-regulatory regions of disease-causing genes (FIG. 5). Indeed, evidence from human genetics studies and experiments in mice suggests that disease-associated genes contain shadow enhancers that likely buffer gene expression against the effect of loss-of-function non-coding mutations.

A recent study used chromatin profiling data across 127 human tissues from the Roadmap Epigenomics Consortium to calculate an ‘enhancer-domain score’ for each human gene^{33,73}. Enhancer-domain scores indicate the amount of redundant regulatory DNA for each gene, based on the total number of predicted enhancers and the redundancy of TF motifs within them. High enhancer-domain scores are predictive of gene pathogenicity, suggesting that the number of shadow enhancers is closely related to the gene’s importance in human disease⁷³. This analysis is consistent with previous observations in fruit flies and mice, where important developmental genes tend to have larger regulatory domains¹¹¹ and contain more enhancers per tissue²⁹.

The strong association between shadow enhancers and developmental and disease-associated genes explains why many targeted deletions of enhancers of these genes cause fairly mild phenotypes or no observable phenotypes in mice^{12,112–116}. Moreover, deletions of ultraconserved enhancers, which retain almost perfect sequence conservation across vertebrates and are located next to important developmental genes, have also led to viable mice with subtle phenotypes^{78,117,118}. With the availability of highly efficient CRISPR–Cas9 genome editing, the number of enhancer-knockout mice that lack observable phenotypes has grown^{18,29,68,78,119}. These studies further suggest that a significant fraction of loss-of-function mutations in human shadow enhancers will cause relatively subtle phenotypes in patients.

Shadow enhancer buffering predicts that loss-of-function genetic variants in human shadow enhancers would have less severe effects on gene expression and phenotypes than variants in non-redundant enhancers. Indeed, genes with redundant enhancer domains are depleted of common and rare non-coding variants associated with gene expression changes⁷³. This pattern indicates that genes with shadow enhancers are more resilient against naturally occurring non-coding mutations in the human population.

It remains to be seen whether shadow enhancers also provide protection against gain-of-function mutations in enhancers that cause misexpression of disease-associated genes. Studies in *D. melanogaster* showed that one shadow enhancer can repress another shadow enhancer in a dominant fashion⁸⁴, suggesting that enhancer mutations causing gene misexpression could, in principle, be buffered by repression from another shadow enhancer. By contrast, both rare and common gain-of-function enhancer variants are associated with congenital malformations¹²⁰, heart disease¹²¹, intellectual disabilities¹²² and cancer^{123–125}, potentially through misexpression or upregulation of important developmental genes. In these examples, it is not always clear whether an additional shadow enhancer

Ultraconserved enhancers
Enhancers overlapping 'ultraconserved' sequences, which are stretches of DNA that share perfect sequence conservation between mouse, rat and human.

Transposon co-option
The process by which a transposon changes its function (for example, becomes a new gene or enhancer) through the introduction of sequence mutations.

was also present. Systematic mutagenesis of human enhancers using massively parallel reporter assays followed by in vivo validation in mice will help to identify how frequently such gain-of-function mutations affect enhancers^{40,126–129}.

Evolution of shadow enhancers

Evolutionary origin of shadow enhancers. Despite their importance, the evolutionary origins of most shadow enhancers are unclear. Like non-redundant enhancers (reviewed in REF.³), shadow enhancers may arise by one of several mechanisms: de novo from existing non-coding DNA, duplication of existing enhancers, or co-option of transposable elements or unrelated enhancers. Another potential mechanism is splitting an enhancer with redundancy across its length into two parts through the insertion of non-functional DNA (FIG. 6). The redundancy of shadow enhancers suggests that they may emerge as a result of duplication events, an idea proposed for some *Drosophila* shadow enhancers¹³. However, there are only few documented examples of such origins^{63,130}, and many shadow enhancers seem

to have little sequence similarity^{79,131}. Some shadow enhancers can arise from transposon co-option events. For example, MER41 endogenous retroviruses (ERVs) have been co-opted to redundantly regulate genes involved in the interferon response¹³². Mammalian-apparent long terminal repeat (LTR) and short interspersed element (SINE) retrotransposons were independently co-opted to redundantly regulate the brain expression of the *Pomc* gene, which is important for the control of food intake¹³³ (TABLE 1). A recent study used enhancer predictions based on eRNA profiling across hundreds of human and mouse cell lines to estimate that 31% of all redundant enhancer pairs in humans and 17% of those in mice have evolved by transposon co-option¹³¹. For most transposon-derived redundant enhancer pairs, both enhancers have evolved through independent transposons co-option events, suggesting that duplication may not be a dominant route of shadow enhancer acquisition. Most shadow enhancers have only partially overlapping activity patterns (TABLE 1), suggesting that one of the main mechanisms of shadow enhancer birth could be through co-option of enhancers with initially non-overlapping activities. Selection may favour the recruitment of shadow enhancers to genes whose robust expression is required for a newly emerging key developmental process (for example, pectoral fins in jawed fish¹⁹).

Evolutionary conservation of shadow enhancers. Given the redundancy of shadow enhancers, it was initially hypothesized that they would be subject to relaxed evolutionary constraint, allowing them to evolve novel regulatory functions¹³. If true, this hypothesis would predict a greater rate of mutations in shadow enhancers than in non-redundant enhancers. In a large group of *D. melanogaster* mesoderm-specific enhancers, shadow enhancers have higher sequence conservation than non-redundant enhancers, and there is no evidence of relaxed constraint on shadow enhancers¹⁶. Among ultraconserved enhancers, many have activity that is redundant with another ultraconserved enhancer in the locus^{29,78,117,118}. This observation is again in contrast to the prediction that shadow enhancers are subject to weak evolutionary constraint. Growing evidence also suggests that evolution acts on groups of shadow enhancers as regulatory units, instead of on each enhancer individually. Similarly to the stabilizing selection that maintains a single enhancer's function¹³⁴, mutations that cause a reduction in the activity of one shadow enhancer could be compensated by other mutations that increase the activity of another shadow enhancer, and vice versa. Indeed, stabilizing selection has been shown to act on shadow enhancers to maintain conserved expression levels across different species^{17,135,136}.

A full understanding of the evolutionary patterns of shadow enhancers remains to emerge, but the data collected so far suggest that shadow enhancers may not be an evolutionarily special and distinct class of enhancers per se. The conservation of shadow enhancers and the growing evidence that individual shadow enhancers can have distinct functions suggest that shadow enhancers can be fine-tuned for multiple purposes^{79,84,86}.




Fig. 5 | Shadow enhancers buffer gene expression against non-coding mutations in disease-causing genes. a | Many genetic disorders are caused by loss-of-function (LoF) mutations in coding regions of disease-causing genes. If the gene is controlled by a single enhancer, a LoF mutation in the enhancer will mimic the loss of gene function in the tissue and the time point of enhancer activity. **b** | If a disease-causing gene is controlled by shadow enhancers, mutations in non-coding regions that deactivate one of the shadow enhancers will be buffered by another shadow enhancer.




Fig. 6 | **Many evolutionary routes potentially lead to shadow enhancer birth.** Proposed mechanisms include mutations in non-coding regions that generate a novel enhancer, duplication of an existing enhancer, splitting of a large enhancer into two by transposable element (TE) insertion, and co-option of either a TE or an unrelated enhancer to become a shadow enhancer. TF, transcription factor.

Perspectives

Work over the last 10 years has shown that enhancer redundancy is a common feature of animal genomes, with shadow enhancers potentially controlling most developmental genes. The primary purpose of this redundancy seems to be providing a mechanism to drive robust developmental patterning, irrespective of genetic and environmental stress. Shadow enhancers can also interact in complex ways to drive finely tuned expression patterns, similar to the intricate interactions between TF-binding sites within an enhancer. Shadow enhancers may also drive the formation of transcriptional condensates or hubs via increased TF recruitment, which may increase the fidelity of transcription. Evidence from human genetics studies indicates that shadow enhancers are key to regulating many disease-associated genes. The importance of shadow enhancers is also underscored by their surprising evolutionary conservation.

There remain a number of open questions in the shadow enhancer field. One of the most persistent questions about shadow enhancer prevalence is whether multiple enhancers are intrinsically capable of regulation that is unachievable by a single enhancer. Many of the ways that shadow enhancers interact (that is, synergistically or repressively) are reminiscent of interactions observed between TF-binding sites within a single enhancer. So why have more than one enhancer? It may be possible that there is a limit on the stretch of DNA that can serve as an enhancer, so multiple enhancers allow there to be more room to encode complex biological functions. Or perhaps the formation of stable transcriptional hubs requires multiple clusters of TF-binding sites spread throughout a locus to recruit the necessary transcriptional machinery. Alternatively, the flexibility of 3D genome organization may allow regulatory information to be encoded in either a single enhancer or multiple shadow enhancers located within

the same topologically associating domain. If true, this suggests that shadow enhancers exist in the genome because there is no selective pressure to consolidate them into a single enhancer. A comprehensive answer to these questions will require several types of experiments. Measuring the activity of large numbers of individual enhancers and shadow enhancer sets may identify the behaviours that are possible with multiple enhancers, but not a single enhancer. Experiments that visualize the dynamic 3D conformation of loci with multiple enhancers would improve our ability to predict how multiple enhancers interact to control a single target gene.

Despite the prevalence of shadow enhancers in animal genomes, their evolutionary origins are largely a mystery. Once present in a genome, shadow enhancers are typically more conserved than other enhancers¹⁶. Some shadow enhancers are even among the most conserved sequences in the genome (that is, ultraconserved enhancers)^{38,118}. Since many shadow enhancers seem to be dispensable for organismal function and display superficial redundancy, their high degree of evolutionary conservation is puzzling. Most shadow enhancer-knockout studies have been performed in laboratory conditions, which do not recapitulate native environments. Therefore, it may be hard to observe the potentially small reductions in fitness that can result in strong purifying selection. Future studies of shadow enhancer mutants in more natural environments may generate a fuller picture of the contributions of enhancer redundancy to organismal fitness.

Finally, our ability to predict the effect of enhancer sequence variation on human phenotypes is still limited. Most trait- and disease-causing variants discovered in genome-wide association studies fall outside coding sequences and are hypothesized to affect enhancer sequences^{137,138}. Similarly, whole-genome sequencing

Topologically associating domain

Large genomic domains (~ 1 Mb) that display more frequent physical contacts between sequences within the same domain than between sequences from different domains.

of patients has identified a growing number of rare non-coding variants that affect developmental genes and are linked to disease^{139–142}. In contrast to findings from genome-wide association studies and whole-genome sequencing studies, disease-associated genes with large redundant regulatory domains show a relative depletion of functional non-coding variants⁷³. How can we synthesize the fact that shadow enhancers can buffer gene expression against sequence variation with the prevalence of disease-associated enhancer mutations? It is possible that disease-causing non-coding variants primarily affect genes lacking shadow enhancers or cause a

gain of enhancer activity, which may not be buffered by the presence of shadow enhancers. Alternatively, variants in shadow enhancers may have a fairly small effect on target gene expression, which can be amplified by the presence of other mutations or the environment, leading to disease. The rapid increase in whole-genome sequencing of individuals^{143–145} combined with large-scale functional assays of human enhancer variant activity^{127,146} will shed more light on the role shadow enhancers play in human disease.

Published online: 12 January 2021

- Shlyueva, D., Stampfel, G. & Stark, A. Transcriptional enhancers: from properties to genome-wide predictions. *Nat. Rev. Genet.* **15**, 272–286 (2014).
- Furlong, E. E. M. & Levine, M. Developmental enhancers and chromosome topology. *Science* **361**, 1341–1345 (2018).
- Long, H. K., Prescott, S. L. & Wysocka, J. Ever-changing landscapes: transcriptional enhancers in development and evolution. *Cell* **167**, 1170–1187 (2016).
- Schoenfelder, S. & Fraser, P. Long-range enhancer-promoter contacts in gene expression control. *Nat. Rev. Genet.* **20**, 437–455 (2019).
- Andersson, R. & Sandelin, A. Determinants of enhancer and promoter activities of regulatory elements. *Nat. Rev. Genet.* **21**, 71–87 (2020).
- Field, A. & Adelman, K. Evaluating enhancer function and transcription. *Annu. Rev. Biochem.* **89**, 213–234 (2020).
- Visel, A., Rubin, E. M. & Pennacchio, L. A. Genomic views of distant-acting enhancers. *Nature* **461**, 199–205 (2009).
- Hoch, M., Schröder, C., Seifert, E. & Jäckle, H. cis-acting control elements for Krüppel expression in the *Drosophila* embryo. *EMBO J.* **9**, 2587–2595 (1990).
- Kassis, J. A. Spatial and temporal control elements of the *Drosophila* engrailed gene. *Genes Dev.* **4**, 433–443 (1990).
- Zeitlinger, J. et al. Whole-genome ChIP-chip analysis of Dorsal, Twist, and Snail suggests integration of diverse patterning processes in the *Drosophila* embryo. *Genes Dev.* **21**, 385–390 (2007).
- Jeong, Y., El-Jaick, K., Roessler, E., Muenke, M. & Epstein, D. J. A functional screen for sonic hedgehog regulatory elements across a 1 Mb interval identifies long-range ventral forebrain enhancers. *Development* **133**, 761–772 (2006).
- Kurokawa, D. et al. Regulation of Otx2 expression and its functions in mouse forebrain and midbrain. *Development* **131**, 3319–3331 (2004).
- Hong, J.-W., Hendrix, D. A. & Levine, M. S. Shadow enhancers as a source of evolutionary novelty. *Science* **321**, 1314 (2008).
This article introduces the term 'shadow enhancer' to describe several enhancers important for dorsal–ventral patterning in the fly embryo and speculates on the evolutionary role of shadow enhancers.
- Barolo, S. Shadow enhancers: frequently asked questions about distributed cis-regulatory information and enhancer redundancy. *Bioessays* **34**, 135–141 (2012).
- Hobert, O. Gene regulation: enhancers stepping out of the shadow. *Curr. Biol.* **20**, R697–R699 (2010).
- Cannavò, E. et al. Shadow enhancers are pervasive features of developmental regulatory networks. *Curr. Biol.* **26**, 38–51 (2016).
In this study, the authors identify more than 1,000 shadow enhancers that pattern *D. melanogaster* mesoderm; sequence conservation suggests that these shadow enhancers play a key role in development.
- Wunderlich, Z. et al. Krüppel expression levels are maintained through compensatory evolution of shadow enhancers. *Cell Rep.* **12**, 1740–1747 (2015).
- Antosova, B. et al. The gene regulatory network of lens induction is wired through meis-dependent shadow enhancers of Pax6. *PLoS Genet.* **12**, e1006441 (2016).
This is one of the first studies to examine the phenotypic impact of double shadow enhancer deletions and shadow enhancer deletions on a sensitized background in mice.
- Letelier, J. et al. A conserved Shh cis-regulatory module highlights a common developmental origin of unpaired and paired fins. *Nat. Genet.* **50**, 504–509 (2018).
- Nolte, C., Jinks, T., Wang, X., Martinez Pastor, M. T. & Krumlauf, R. Shadow enhancers flanking the HoxB cluster direct dynamic Hox expression in early heart and endoderm development. *Dev. Biol.* **383**, 158–173 (2013).
- Swami, M. Transcription: shadow enhancers confer robustness. *Nat. Rev. Genet.* **11**, 454 (2010).
- Ghivasvand, N. M. et al. Deletion of a remote enhancer near ATOH7 disrupts retinal neurogenesis, causing NCRNA disease. *Nat. Neurosci.* **14**, 578–586 (2011).
- Watts, J. A. et al. Study of FoxA pioneer factor at silent genes reveals Rfx-repressed enhancer at Cdx2 and a potential indicator of esophageal adenocarcinoma development. *PLoS Genet.* **7**, e1002277 (2011).
- Lagha, M., Bothma, J. P. & Levine, M. Mechanisms of transcriptional precision in animal development. *Trends Genet.* **28**, 409–416 (2012).
- Stefanakis, N., Carrera, I. & Hobert, O. Regulatory logic of pan-neuronal gene expression in *C. elegans*. *Neuron* **87**, 733–750 (2015).
- Frankel, N. et al. Phenotypic robustness conferred by apparently redundant transcriptional enhancers. *Nature* **466**, 490–493 (2010).
This article describes the phenotypic impact of shadow enhancer deletions on bristle formation in fly larvae. Along with Perry et al. (2010), it was among the first to show that shadow enhancers are required for proper development under stressful conditions.
- Perry, M. W., Boettiger, A. N., Bothma, J. P. & Levine, M. Shadow enhancers foster robustness of *Drosophila* gastrulation. *Curr. Biol.* **20**, 1562–1567 (2010).
This article describes the phenotypic impact of shadow enhancer deletions on gastrulation in fly embryos. Along with Frankel et al. (2010), it was among the first to show that shadow enhancers are required for proper development under stressful conditions.
- Perry, M. W., Boettiger, A. N. & Levine, M. Multiple enhancers ensure precision of gap gene-expression patterns in the *Drosophila* embryo. *Proc. Natl Acad. Sci. USA* **108**, 13570–13575 (2011).
- Osterwalder, M. et al. Enhancer redundancy provides phenotypic robustness in mammalian development. *Nature* **554**, 239–243 (2018).
This study uses mouse ENCODE data and systematic deletions (both individual and pairs) of ten different mouse limb enhancers to show widespread redundancy in mammalian genomes.
- Sagai, T. et al. SHH signaling directed by two oral epithelium-specific enhancers controls tooth and oral development. *Sci. Rep.* **7**, 13004 (2017).
- Andersson, R. et al. An atlas of active enhancers across human cell types and tissues. *Nature* **507**, 455–461 (2014).
- Yue, F. et al. A comparative encyclopedia of DNA elements in the mouse genome. *Nature* **515**, 355–364 (2014).
- Roadmap Epigenomics Consortium, et al. Integrative analysis of 111 reference human epigenomes. *Nature* **518**, 317–330 (2015).
- Abascal, F. et al. Expanded encyclopaedias of DNA elements in the human and mouse genomes. *Nature* **583**, 699–710 (2020).
- Gorkin, D. U. et al. An atlas of dynamic chromatin landscapes in mouse fetal development. *Nature* **583**, 744–751 (2020).
- Dekker, J. et al. The 4D nucleome project. *Nature* **549**, 219–226 (2017).
- Visel, A., Minovitsky, S., Dubchak, I. & Pennacchio, L. A. VISTA Enhancer Browser—a database of tissue-specific human enhancers. *Nucleic Acids Res.* **35**, D88–D92 (2007).
- Pennacchio, L. A. et al. In vivo enhancer analysis of human conserved non-coding sequences. *Nature* **444**, 499–502 (2006).
- Manning, L. et al. A resource for manipulating gene expression and analyzing cis-regulatory modules in the *Drosophila* CNS. *Cell Rep.* **2**, 1002–1013 (2012).
- Kvon, E. Z. Using transgenic reporter assays to functionally characterize enhancers in animals. *Genomics* **106**, 185–192 (2015).
- Gallo, S. M. et al. REDfly v3.0: toward a comprehensive database of transcriptional regulatory elements in *Drosophila*. *Nucleic Acids Res.* **39**, D118–D123 (2011).
- Bonn, S. et al. Tissue-specific analysis of chromatin state identifies temporal signatures of enhancer activity during embryonic development. *Nat. Genet.* **44**, 148–156 (2012).
- Kvon, E. Z. et al. Genome-scale functional characterization of *Drosophila* developmental enhancers in vivo. *Nature* **512**, 91–95 (2014).
- Lopes, R., Korkmaz, G. & Agami, R. Applying CRISPR-Cas9 tools to identify and characterize transcriptional enhancers. *Nat. Rev. Mol. Cell Biol.* **17**, 597–604 (2016).
- Catarino, R. R. & Stark, A. Assessing sufficiency and necessity of enhancer activities for gene expression and the mechanisms of transcription activation. *Genes Dev.* **32**, 202–223 (2018).
- Klein, J. C., Chen, W., Gasperini, M. & Shendure, J. Identifying novel enhancer elements with CRISPR-based screens. *ACS Chem. Biol.* **13**, 326–332 (2018).
- Wright, J. B. & Sanjana, N. E. CRISPR screens to discover functional noncoding elements. *Trends Genet.* **32**, 526–529 (2016).
- Garcia, H. G., Tikhonov, M., Lin, A. & Gregor, T. Quantitative imaging of transcription in living *Drosophila* embryos links polymerase activity to patterning. *Curr. Biol.* **23**, 2140–2145 (2013).
- Lucas, T. et al. Live imaging of bicoid-dependent transcription in *Drosophila* embryos. *Curr. Biol.* **23**, 2135–2139 (2013).
- Twissell, D., Yamaguchi, J., Wing, R. A., Ushiba, J. & McCormick, S. Promoter analysis of genes that are coordinately expressed during pollen development reveals pollen-specific enhancer sequences and shared regulatory elements. *Genes Dev.* **5**, 496–507 (1991).
- Poulsen, C. & Chua, N. H. Dissection of 5' upstream sequences for selective expression of the Nicotiana plumbaginifolia rbcS-8B gene. *Mol. Gen. Genet.* **214**, 16–23 (1988).
- Camprodón, F. J. & Castellí-Gair, J. E. Ultrabithorax protein expression in breakpoint mutants: localization of single, co-operative and redundant cis regulatory elements. *Roux's Arch. Dev. Biol.* **203**, 411–421 (1994).
- Bachmann, A. & Knust, E. Dissection of cis-regulatory elements of the *Drosophila* gene *Serrate*. *Dev. Genes Evol.* **208**, 346–351 (1998).
- Schroeder, M. D. et al. Transcriptional control in the segmentation gene network of *Drosophila*. *PLoS Biol.* **2**, E271 (2004).
- Pappu, K. S. et al. Dual regulation and redundant function of two eye-specific enhancers of the *Drosophila* retinal determination gene *dachshund*. *Development* **132**, 2895–2905 (2005).

56. Yao, L. C. et al. Multiple modular promoter elements drive graded brinker expression in response to the Dpp morphogen gradient. *Development* **135**, 2183–2192 (2008).
57. Ertzler, R. et al. Cooperation of sonic hedgehog enhancers in midline expression. *Dev. Biol.* **301**, 578–589 (2007).
58. Nakada, Y., Parab, P., Simmons, A., Omer-Abdalla, A. & Johnson, J. E. Separable enhancer sequences regulate the expression of the neural bHLH transcription factor neurogenin 1. *Dev. Biol.* **271**, 479–487 (2004).
59. Menke, D. B., Guenther, C. & Kingsley, D. M. Dual hindlimb control elements in the *Tbx4* gene and region-specific control of bone size in vertebrate limbs. *Development* **135**, 2543–2553 (2008).
60. Li, Q., Peterson, K. R., Fang, X. & Stamatiyanopoulos, G. Locus control regions. *Blood* **100**, 3077–3086 (2002).
61. Grosveld, F., van Assendelft, G. B., Greaves, D. R. & Kollias, G. Position-independent, high-level expression of the human beta-globin gene in transgenic mice. *Cell* **51**, 975–985 (1987).
62. Zhou, X. & Sigmund, C. D. Chorionic enhancer is dispensable for regulated expression of the human renin gene. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **294**, R279 (2008).
63. Allan, C. M., Walker, D. & Taylor, J. M. Evolutionary duplication of a hepatic control region in the human apolipoprotein E gene locus. Identification of a second region that confers high level and liver-specific expression of the human apolipoprotein E gene in transgenic mice. *J. Biol. Chem.* **270**, 26278–26281 (1995).
64. Babbitt, C. C., Markstein, M. & Gray, J. M. Recent advances in functional assays of transcriptional enhancers. *Genomics* **106**, 137–139 (2015).
65. Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. *Cell* **155**, 934–947 (2013).
66. Whyte, W. A. et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. *Cell* **153**, 307–319 (2013).
67. Parker, S. C. J. et al. Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants. *Proc. Natl Acad. Sci. USA* **110**, 17921–17926 (2013).
68. Hay, D. et al. Genetic dissection of the α -globin super-enhancer in vivo. *Nat. Genet.* **48**, 895–903 (2016).
69. Pott, S. & Lieb, J. D. What are super-enhancers? *Nat. Genet.* **47**, 8–12 (2015).
70. Dukler, N., Gulko, B., Huang, Y.-F. & Siepel, A. Is a super-enhancer greater than the sum of its parts? *Nat. Genet.* **49**, 2–3 (2016).
71. Li, W., Notani, D. & Rosenfeld, M. G. Enhancers as non-coding RNA transcription units: recent insights and future perspectives. *Nat. Rev. Genet.* **17**, 207–223 (2016).
72. Arner, E. et al. Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells. *Science* **347**, 1010–1014 (2015).
73. Wang, X. & Goldstein, D. B. Enhancer domains predict gene pathogenicity and inform gene discovery in complex disease. *Am. J. Hum. Genet.* **106**, 215–233 (2020).
This study uses human chromatin data from the Roadmap Epigenomics Consortium to show that human genes with large redundant domains are depleted of cis-acting genetic variants that disrupt gene expression, and their expression is buffered against the effects of disruptive non-coding mutations.
74. Arnold, C. D. et al. Genome-wide quantitative enhancer activity maps identified by STARR-seq. *Science* **339**, 1074–1077 (2013).
75. Wang, H. et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. *Cell* **153**, 910–918 (2013).
76. Joung, J. K. & Sander, J. D. TALENs: a widely applicable technology for targeted genome editing. *Nat. Rev. Mol. Cell Biol.* **14**, 49–55 (2013).
77. Doudna, J. A. & Charpentier, E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. *Science* **346**, 1258096 (2014).
78. Dickel, D. E. et al. Ultraconserved enhancers are required for normal development. *Cell* **172**, 491–499. e15 (2018).
79. Waymack, R., Fletcher, A., Enciso, G. & Wunderlich, Z. Shadow enhancers can suppress input transcription factor noise through distinct regulatory logic. *eLife* **9**, e59351 (2020).
This study in fly embryos shows that a pair of shadow enhancers, each regulated by different TFs,
80. Visel, A. et al. Functional autonomy of distant-acting human enhancers. *Genomics* **93**, 509–513 (2009).
81. Bothma, J. P. et al. Enhancer additivity and non-additivity are determined by enhancer strength in the Drosophila embryo. *eLife* **4**, e07956 (2015).
This article investigates how the activities of individual shadow enhancers interact to establish their combined activity in fly embryos and finds a wide range of possible interactions (superadditive, additive, subadditive and repressive) that may depend on the strength of the individual enhancers.
82. Lam, D. D. et al. Partially redundant enhancers cooperatively maintain mammalian *Pomc* expression above a critical functional threshold. *PLoS Genet.* **11**, e1004935 (2015).
83. Scholtes, C., Biette, K. M., Harden, T. T. & DePace, A. H. Signal integration by shadow enhancers and enhancer duplications varies across the Drosophila embryo. *Cell Rep.* **26**, 2407–2418.e5 (2019).
84. El-Sherif, E. & Levine, M. Shadow enhancers mediate dynamic shifts of gap gene expression in the Drosophila embryo. *Curr. Biol.* **26**, 1164–1169 (2016).
85. Dunipace, L., Ozdemir, A. & Stathopoulos, A. Complex interactions between cis-regulatory modules in native conformation are critical for Drosophila snail expression. *Development* **138**, 4075–4084 (2011).
86. Dunipace, L., Ákos, Z. & Stathopoulos, A. Coacting enhancers can have complementary functions within gene regulatory networks and promote canalization. *PLoS Genet.* **15**, e1008525 (2019).
87. Yan, J. et al. Regulatory logic driving stable levels of defective proventriculus expression during terminal photoreceptor specification in flies. *Development* **144**, 844–855 (2017).
88. Bentovim, L., Harden, T. T. & DePace, A. H. Transcriptional precision and accuracy in development: from measurements to models and mechanisms. *Development* **144**, 3855–3866 (2017).
89. Robson, M. I., Ringel, A. R. & Mundlos, S. Regulatory landscaping: how enhancer-promoter communication is sculpted in 3D. *Mol. Cell* **74**, 1110–1122 (2019).
90. Zabidi, M. A. & Stark, A. Regulatory enhancer-core-promoter communication via transcription factors and cofactors. *Trends Genet.* **32**, 801–814 (2016).
91. Proudhon, C. et al. Active and inactive enhancers cooperate to exert localized and long-range control of gene regulation. *Cell Rep.* **15**, 2159–2169 (2016).
92. Jiang, T. et al. Identification of multi-loci hubs from 4C-seq demonstrates the functional importance of simultaneous interactions. *Nucleic Acids Res.* **44**, 8714–8725 (2016).
93. Hughes, J. R. et al. Analysis of hundreds of cis-regulatory landscapes at high resolution in a single, high-throughput experiment. *Nat. Genet.* **46**, 205–212 (2014).
94. Allahyar, A. et al. Enhancer hubs and loop collisions identified from single-allele topologies. *Nat. Genet.* **50**, 1151–1160 (2018).
95. Fukaya, T., Lim, B. & Levine, M. Enhancer control of transcriptional bursting. *Cell* **166**, 358–368 (2016).
96. Lim, B., Heist, T., Levine, M. & Fukaya, T. Visualization of transvection in living Drosophila embryos. *Mol. Cell* **70**, 287–296.e6 (2018).
97. Godin, A. G., Lounis, B. & Cognet, L. Super-resolution microscopy approaches for live cell imaging. *Biophys. J.* **107**, 1777–1784 (2014).
98. Schermelleh, L. et al. Super-resolution microscopy demystified. *Nat. Cell Biol.* **21**, 72–84 (2019).
99. Chen, H. et al. Dynamic interplay between enhancer-promoter topology and gene activity. *Nat. Genet.* **50**, 1296–1303 (2018).
100. Chen, H. & Gregor, T. in *RNA Tagging: Methods and Protocols* (ed. Heinlein, M.) 373–384 (Springer, 2020).
101. Reiter, F., Wienerroither, S. & Stark, A. Combinatorial function of transcription factors and cofactors. *Curr. Opin. Genet. Dev.* **43**, 73–81 (2017).
102. Sabari, B. R. et al. Coactivator condensation at super-enhancers links phase separation and gene control. *Science* **361**, eaar3958 (2018).
103. Hnisz, D., Shrinivas, K., Young, R. A., Chakraborty, A. K. & Sharp, P. A. A phase separation model for transcriptional control. *Cell* **169**, 13–23 (2017).
104. Montavon, T. et al. A regulatory archipelago controls Hox genes transcription in digits. *Cell* **147**, 1132–1145 (2011).
105. Cho, W.-K. et al. Mediator and RNA polymerase II clusters associate in transcription-dependent condensates. *Science* **361**, 412–415 (2018).
106. Jackson, D. A., Iborra, F. J., Manders, E. M. & Cook, P. R. Numbers and organization of RNA polymerases, nascent transcripts, and transcription units in HeLa nuclei. *Mol. Biol. Cell* **9**, 1523–1536 (1998).
107. Cisse, I. I. et al. Real-time dynamics of RNA polymerase II clustering in live human cells. *Science* **341**, 664–667 (2013).
108. Benabdallah, N. S. et al. Decreased enhancer-promoter proximity accompanying enhancer activation. *Mol. Cell* **76**, 473–484.e7 (2019).
109. Alexander, J. M. et al. Live-cell imaging reveals enhancer-dependent Sox2 transcription in the absence of enhancer proximity. *eLife* **8**, e41769 (2019).
110. Tsai, A., Alves, M. R. & Crocker, J. Multi-enhancer transcriptional hubs confer phenotypic robustness. *eLife* **8**, e45325 (2019).
This study describes how shadow enhancers may be critical for establishing or maintaining local regions of high TF concentrations required for achieving a certain threshold of gene expression.
111. Zeitlinger, J. & Stark, A. Developmental gene regulation in the era of genomics. *Dev. Biol.* **339**, 230–239 (2010).
112. Cretekos, C. J. et al. Regulatory divergence modifies limb length between mammals. *Genes Dev.* **22**, 141–151 (2008).
113. Manis, J. P. et al. Class switching in B cells lacking 3' immunoglobulin heavy chain enhancers. *J. Exp. Med.* **188**, 1421–1431 (1998).
114. Bender, M. A. et al. Description and targeted deletion of 5' hypersensitive site 5 and 6 of the mouse beta-globin locus control region. *Blood* **92**, 4394–4403 (1998).
115. Fiering, S. et al. Targeted deletion of 5'HS2 of the murine beta-globin LCR reveals that it is not essential for proper regulation of the beta-globin locus. *Genes Dev.* **9**, 2203–2213 (1995).
116. Attanasio, C. et al. Fine tuning of craniofacial morphology by distant-acting enhancers. *Science* **342**, 1241006 (2013).
117. Nolte, M. J. et al. Functional analysis of limb transcriptional enhancers in the mouse. *Evol. Dev.* **16**, 207–223 (2014).
118. Ahituv, N. et al. Deletion of ultraconserved elements yields viable mice. *PLoS Biol.* **5**, e234 (2007).
119. Cunningham, T. J., Lancman, J. J., Berenguer, M., Dong, P. D. S. & Duester, G. Genomic knockout of two presumed forelimb Tbx5 enhancers reveals they are nonessential for limb development. *Cell Rep.* **23**, 3146–3151 (2018).
120. Hill, R. E. & Lettice, L. A. Alterations to the remote control of *Shh* gene expression cause congenital abnormalities. *Phil. Trans. R. Soc. B* **368**, 20120357 (2013).
121. Gupta, R. M. et al. A genetic variant associated with five vascular diseases is a distal regulator of endothelin-1 gene expression. *Cell* **170**, 522–533. e15 (2017).
122. Huang, L. et al. A noncoding, regulatory mutation implicates HCFC1 in nonsyndromic intellectual disability. *Am. J. Hum. Genet.* **91**, 694–702 (2012).
123. Wright, J. B., Brown, S. J. & Cole, M. D. Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism in colorectal cancer cells. *Mol. Cell Biol.* **30**, 1411–1420 (2010).
124. Sur, I. K. et al. Mice lacking a Myc enhancer that includes human SNP rs6983267 are resistant to intestinal tumors. *Science* **338**, 1360–1363 (2012).
125. Oktay, Y. et al. IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation. *Sci. Rep.* **6**, 27569 (2016).
126. Inoue, F. & Ahituv, N. Decoding enhancers using massively parallel reporter assays. *Genomics* **106**, 159–164 (2015).
127. Kwon, E. Z. et al. Comprehensive in vivo interrogation reveals phenotypic impact of human enhancer variants. *Cell* **180**, 1262–1271.e15 (2020).
128. Kircher, M. et al. Saturation mutagenesis of twenty disease-associated regulatory elements at single base-pair resolution. *Nat. Commun.* **10**, 3583 (2019).
129. Canver, M. C. et al. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. *Nature* **527**, 192–197 (2015).
130. Saleque, S. et al. Dyad symmetry within the mouse 3' IgH regulatory region includes two virtually identical enhancers (C alpha3'E and hs3). *J. Immunol.* **158**, 4780–4787 (1997).
131. Barth, N. K. H., Li, L. & Taher, L. Independent transposon exaptation is a widespread mechanism of

- redundant enhancer evolution in the mammalian genome. *Genome Biol. Evol.* **12**, 1–17 (2020).
132. Chuong, E. B., Elde, N. C. & Feschotte, C. Regulatory evolution of innate immunity through co-option of endogenous retroviruses. *Science* **351**, 1083–1087 (2016).
 133. Franchini, L. F. et al. Convergent evolution of two mammalian neuronal enhancers by sequential exaptation of unrelated retroposons. *Proc. Natl Acad. Sci. USA* **108**, 15270–15275 (2011).
 134. Ludwig, M. Z., Bergman, C., Patel, N. H. & Kreitman, M. Evidence for stabilizing selection in a eukaryotic enhancer element. *Nature* **403**, 564–567 (2000).
 135. Arnold, C. D. et al. Quantitative genome-wide enhancer activity maps for five *Drosophila* species show functional enhancer conservation and turnover during cis-regulatory evolution. *Nat. Genet.* **46**, 685–692 (2014).
 136. Berthelot, C., Villar, D., Horvath, J. E., Odom, D. T. & Flicek, P. Complexity and conservation of regulatory landscapes underlie evolutionary resilience of mammalian gene expression. *Nat. Ecol. Evol.* **2**, 152–163 (2018).
 137. Maurano, M. T. et al. Systematic localization of common disease-associated variation in regulatory DNA. *Science* **337**, 1190–1195 (2012).
 138. McGuire, A. L. et al. The road ahead in genetics and genomics. *Nat. Rev. Genet.* **21**, 581–596 (2020).
 139. Short, P. J. et al. De novo mutations in regulatory elements in neurodevelopmental disorders. *Nature* **555**, 611–616 (2018).
 140. Turro, E. et al. Whole-genome sequencing of patients with rare diseases in a national health system. *Nature* **583**, 96–102 (2020).
 141. Richter, F. et al. Genomic analyses implicate noncoding de novo variants in congenital heart disease. *Nat. Genet.* **52**, 769–777 (2020).
 142. Turner, T. N. et al. Genomic patterns of De novo mutation in simplex autism. *Cell* **171**, 710–722.e12 (2017).
 143. Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* **581**, 434–443 (2020).
 144. 1000 Genomes Project Consortium. et al. A map of human genome variation from population-scale sequencing. *Nature* **467**, 1061–1073 (2010).
 145. Taliun, D. et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed program. Preprint at *bioRxiv* <https://doi.org/10.1101/563866> (2019).
 146. van Arensbergen, J. et al. High-throughput identification of human SNPs affecting regulatory element activity. *Nat. Genet.* **51**, 1160–1169 (2019).
 147. O'Meara, M. M. et al. Cis-regulatory mutations in the *Caenorhabditis elegans* homeobox gene locus *cog-1* affect neuronal development. *Genetics* **181**, 1679–1686 (2009).
 148. Fujioka, M. & Jaynes, J. B. Regulation of a duplicated locus: *Drosophila* sloppy paired is replete with functionally overlapping enhancers. *Dev. Biol.* **362**, 309–319 (2012).
 149. Bell, K., Skier, K., Chen, K. H. & Gergen, J. P. Two pair-rule responsive enhancers regulate wingless transcription in the *Drosophila* blastoderm embryo. *Dev. Dyn.* **249**, 556–572 (2020).
 150. Kalay, G., Lachowicz, J., Rosas, U., Dome, M. R. & Wittkopp, P. Redundant and cryptic enhancer activities of the *Drosophila* yellow gene. *Genetics* **212**, 343–360 (2019).
 151. Johnson, W. A., McCormick, C. A., Bray, S. J. & Hirsh, J. A neuron-specific enhancer of the *Drosophila* dopa decarboxylase gene. *Genes Dev.* **3**, 676–686 (1989).
 152. Torbey, P. et al. Cooperation, cis-interactions, versatility and evolutionary plasticity of multiple cis-acting elements underlie *krox20* hindbrain regulation. *PLoS Genet.* **14**, e1007581 (2018).
 153. Yao, Y. et al. Cis-regulatory architecture of a brain signaling center predates the origin of chordates. *Nat. Genet.* **48**, 575–580 (2016).
 154. de Souza, F. S. J. et al. Identification of neuronal enhancers of the proopiomelanocortin gene by transgenic mouse analysis and phylogenetic footprinting. *Mol. Cell. Biol.* **25**, 3076–3086 (2005).
 155. Degenhardt, K. R. et al. Distinct enhancers at the *Pax3* locus can function redundantly to regulate neural tube and neural crest expressions. *Dev. Biol.* **339**, 519–527 (2010).
 156. McGreal-Estrada, R. S., Wolf, L. V. & Cvekl, A. Promoter-enhancer looping and shadow enhancers of the mouse α -crystallin locus. *Biol. Open* **7**, bio036897 (2018).
 157. Berlivet, S. et al. Clustering of tissue-specific sub-TADs accompanies the regulation of *HoxA* genes in developing limbs. *PLoS Genet.* **9**, e1004018 (2013).
 158. Will, A. J. et al. Composition and dosage of a multipartite enhancer cluster control developmental expression of *Ihh* (Indian hedgehog). *Nat. Genet.* **49**, 1539–1545 (2017).
 159. Miesfeld, J. B. et al. The *Atoh7* remote enhancer provides transcriptional robustness during retinal ganglion cell development. *Proc. Natl Acad. Sci. USA* **117**, 21690–21700 (2020).
 160. Dimanlig, P. V., Faber, S. C., Auerbach, W., Makarenkova, H. P. & Lang, R. A. The upstream ectoderm enhancer in *Pax6* has an important role in lens induction. *Development* **128**, 4415–4424 (2001).
 161. Hui, C. C. & Joyner, A. L. A mouse model of Greig cephalopolysyndactyly syndrome: the extra-toesJ mutation contains an intragenic deletion of the *Gli3* gene. *Nat. Genet.* **3**, 241–246 (1993).
 162. Hogan, B. L. et al. Small eyes (*Sey*): a homozygous lethal mutation on chromosome 2 which affects the differentiation of both lens and nasal placodes in the mouse. *J. Embryol. Exp. Morphol.* **97**, 95–110 (1986).
 163. Hill, R. E. et al. Mouse small eye results from mutations in a paired-like homeobox-containing gene. *Nature* **354**, 522–525 (1991).

Acknowledgements

This work was supported by US National Institutes of Health grants R01HD095246 (to Z.W.) and R00HG009682 (to E.Z.K.). R.W. was supported by an ARCS Foundation award. The authors thank A. Visel, D. Dickel, A. Stark, D. Shlyueva and the reviewers for helpful comments on the manuscript.

Author contributions

All authors researched the literature and wrote the article. E.Z.K., R.W. and Z.W. substantially contributed to discussions of the content, and reviewed and/or edited the manuscript before submission.

Competing interests

The authors declare no competing interests.

Peer review information

Nature Reviews Genetics thanks A. Cvekl, M. Levine and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© Springer Nature Limited 2021